NCT06922539View on ClinicalTrials.gov

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

October 1, 2028

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Fenretinide

Intravenous administration

DRUG

Fenretinide

Intravenous administration

All Listed Sponsors
lead

SciTech Development, Inc.

INDUSTRY

NCT06922539 - ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter